Welcome to our dedicated page for Biodesix news (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on Biodesix stock.
Biodesix, Inc. (BDSX) is a trailblazing diagnostic solutions company specialized in the development and commercialization of blood-based molecular diagnostic tests. These tests advance the standard of care in oncology by providing invaluable data to help patients and their doctors make more informed decisions based on a patient's unique molecular profile. This approach is at the heart of precision medicine, aiming to provide the right treatment to the right patient at the right time.
The company is particularly focused on lung disease and operates in a single segment dedicated to providing diagnostic testing services. Biodesix partners with pharmaceutical companies to develop and commercialize diagnostic tests that accelerate drug development pipelines and bring effective therapies to the market.
Among its notable products are two commercialized tests, VeriStrat® and GeneStrat™, which offer rapid results within 72 hours and do not require tissue samples. These tests enable quicker and more precise treatment decisions, facilitating optimal patient care.
Biodesix's revenue streams come from two primary sources: providing diagnostic testing services related to blood-based lung and COVID-19 tests, and offering biopharmaceutical companies services for diagnostic research, clinical trial testing, and companion diagnostics development. These services are generally performed outside the clinical setting and are governed by individual contracts with third parties.
Recently, Biodesix has been in the news for various significant developments. The latest updates highlight the company's ongoing projects, partnerships, and achievements in the diagnostic field. Stay tuned for more updates as Biodesix continues to innovate in precision medicine and diagnostic solutions.
Biodesix (Nasdaq: BDSX), a leading diagnostic solutions company, has announced it will release its second quarter 2024 financial results on August 7, 2024, after the market closes. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a general business update. Interested parties can register for the webcast online, and analysts wishing to participate in the Q&A session should use a separate link. A replay of the webcast will be available on Biodesix's investor website approximately two hours after the call concludes. Participants are advised to join 15 minutes before the start time.
Biodesix (Nasdaq: BDSX) has been named to Inc. Magazine’s 2024 Best Workplaces list. The accolade results from an in-depth, data-driven process identifying American companies with exceptional workplace cultures. Biodesix, a diagnostic solutions leader, was one of 543 honorees selected from thousands of submissions. The recognition follows a comprehensive employee survey by Quantum Workplace, focusing on management effectiveness, perks, recognition, and overall culture. Founded in 2006, Biodesix reported high double-digit revenue growth and a 93% employee engagement score. CEO Scott Hutton emphasized the company's commitment to a culture of excellence.
Biodesix, a diagnostic solutions company specializing in lung disease, has announced its participation in two investor conferences in June 2024. CEO Scott Hutton will present at the William Blair 44th Annual Growth Stock Conference on June 4 in Chicago, IL, at 10:40 AM CT. He will also present at the Jefferies Global Healthcare Conference on June 6 in New York, NY, at 8:30 AM ET. Both presentations will be webcast live and available for replay in the Investors section of Biodesix's website.
Biodesix announced that it will present new data on the Nodify XL2 test at the 2024 ATS International Conference. The data focuses on the test's ability to identify benign lung nodules in patients with emphysema. The presentation will review a subgroup analysis from the ORACLE study involving 280 patients, demonstrating high negative predictive value of the test, helping to rule out lung cancer irrespective of emphysema status. Dr. Arthur Romero from UNLV will present the findings, suggesting that the test can help avoid unnecessary procedures, thereby allowing timely emphysema treatments.
Biodesix, Inc. (Nasdaq: BDSX) announced first-quarter 2024 results showcasing total revenue of $14.8 million, a 64% year-over-year increase, and 7th consecutive quarter of >50% growth in Lung Diagnostic test volume. The company raised $55 million in gross proceeds from a public offering. Biodesix reported a record quarterly gross profit margin of 79% and a Net Loss improvement of 27%. The company aims to reach profitability by growing revenue and maintaining cost discipline.
Biodesix, Inc. (Nasdaq: BDSX) will participate in the 2024 RBCCM Global Healthcare Conference, with CEO Scott Hutton hosting investor meetings. The conference will take place from May 14-15, 2024, in New York, NY. The presentation will be webcast live and available for replay on Biodesix's website.
FAQ
What does Biodesix, Inc. specialize in?
What are some of Biodesix's key products?
How does Biodesix contribute to precision medicine?
What services does Biodesix provide to biopharmaceutical companies?
What are Biodesix's primary revenue sources?
How quickly can Biodesix's tests provide results?
Does Biodesix require tissue samples for its tests?
What recent achievements has Biodesix made?
Is Biodesix focused solely on oncology diagnostics?
What is the ticker symbol for Biodesix, Inc. on the stock market?
